- Details
- At the 2024 LUGPA annual meeting, Gautam Jayram discusses key updates in bladder and kidney cancer management. Topics include intermediate-risk bladder cancer, BCG-unresponsive disease, immunotherapy for muscle-invasive bladder cancer, adjuvant pembrolizumab for high-risk renal cell carcinoma, and CA9 PET imaging for kidney cancer. He also shares survey data highlighting community urology's growin...
|
- Details
- Leslie Ballas speaks with Gautier Marcq about a JCO publication comparing whole pelvis versus bladder-only radiotherapy in muscle-invasive bladder cancer. The study, analyzing data from ten Canadian academic centers, demonstrates improved cancer-specific and overall survival with whole pelvis radiation therapy. The discussion explores the study's methodology, including the use of IPTW analysis to...
|
- Details
- Alicia Morgans speaks with Jonathan Rosenberg about two novel therapies presented at ESMO 2024. The discussion centers on BL-B01D1, a bispecific antibody-drug conjugate targeting EGFR and HER3 in advanced urothelial cancer, which shows promising early results with a 40% response rate in previously treated patients. The conversation also explores NKT2152, a HIF2a inhibitor for renal cell carcinoma,...
|
- Details
- Leslie Ballas speaks with Kimberley about quality of life considerations for bladder cancer patients undergoing trimodality therapy (TMT), following discussions at the Bladder Cancer Advocacy Network Think Tank. The conversation explores various aspects of patient outcomes, including sexual health differences between men and women, the rarity of salvage cystectomy, and challenges in collecting qua...
|
- Details
- Alicia Morgans hosts Jonathan Rosenberg to discuss the five-year outcomes from EV-103 Cohort A, examining enfortumab vedotin plus pembrolizumab in cisplatin-ineligible advanced urothelial cancer patients. The conversation highlights unprecedented long-term results, with over 40% of patients alive at five years—a dramatic improvement from historical survival rates of approximately 3% with tradition...
|
- Details
- Thomas Powles joins Zachary Klaassen to discuss the NIAGARA trial results. The phase III study examines the addition of durvalumab to cisplatin-based chemotherapy in the perioperative setting for muscle-invasive bladder cancer, representing the largest trial in this space with 1,000 patients. The conversation highlights significant improvements in event-free survival, pathological complete respons...
|
- Details
- Thomas Powles discusses an exploratory nectin-4 biomarker analysis from the EV-302 trial. The conversation examines the role of nectin-4 expression in enfortumab vedotin plus pembrolizumab (EV-Pembro) therapy for bladder cancer, highlighting consistent benefits across expression levels compared to chemotherapy. While over 90% of patients express high levels of nectin-4, the discussion emphasizes t...
|
- Details
- Zachary Klaassen speaks with Sarah Psutka about cognitive resilience in bladder cancer care. Dr. Psutka explains how cancer treatment, from surgery to chemotherapy, can significantly impact cognitive function, with up to a third of patients experiencing persistent postoperative cognitive dysfunction. She emphasizes the shift from focusing solely on physical frailty to understanding patients' compl...
|
- Details
- Ashish Kamat talks with Andrea Apolo about implementing new treatment standards in bladder cancer, focusing on the recent EV-302 and CheckMate-901 trials. Dr. Apolo explains how enfortumab vedotin plus pembrolizumab has emerged as the new standard of care for metastatic urothelial carcinoma, showing superior survival outcomes compared to traditional platinum-based chemotherapy. They explore the ch...
|
- Details
- Seth Lerner discusses the SWOG study on standard versus extended lymphadenectomy for muscle-invasive bladder cancer published October 2024 in the New England Journal of Medicine. Dr. Lerner describes the trial's background, design, and key findings. The study, involving 592 patients with a median follow-up of 6.1 years, shows no benefit in disease-free or overall survival with extended lymphadenec...
|
